Catherine Rougeot

USPTO Granted Patents = 18 (Patent Applications = 5)

CIPO Patents = 7

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 2.4

ph-index = 6

Forward Citations = 62(Granted Patents)

Location History:

Chevreu, FR (2004)
Hameau de Talon, FR (2008)
Chevreuse, FR (2003 - 2017)

Company Filing History:

Centre National De La Recherche Scientifique

patents

1 out of 1

Instituto Gulbenkian De Cienca

patent

4. 1 out of 1

Instituto Gulbekian De Cienca

patent

where one patent can have more than one assignee

Years Active: 2003-2017

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9714951 - Pharmaceutical compositions containing peptides derived from human BPLP protein (2017-07-25),

2. 9403871 - Methods for treating pain by administering peptides derived from human basic proline-rich lacrimal protein (2016-08-02),

3. 9273094 - Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases (2016-03-01),

4. 8895251 - Method for detecting human BPLP protein or a maturation product thereof (2014-11-25),

5. 8889827 - Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases (2014-11-18),

6. 8642729 - Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases (2014-02-04),

7. 8168770 - Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens (2012-05-01),

8. 8017571 - Peptides derived from human BPLP protein (2011-09-13),

9. 7851603 - Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens (2010-12-14),

10. 7732563 - Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens (2010-06-08),

11. 7625713 - Process for identifying a ligand that binds to the NEP binding site for the SMR1 pentapeptide (2009-12-01),

12. 7429448 - Therapeutic use of the SMR1 protein and active derivatives thereof (2008-09-30),

13. 7423020 - Treatment of mood disorders by administration of SMR1 (2008-09-09),

14. 7387778 - Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders (2008-06-17),

15. 7153833 - Therapeutic uses of SMR1 peptides (2006-12-26),

Title: The Impactful Innovations of Inventor Catherine Rougeot

Introduction: Catherine Rougeot is a distinguished inventor based in Chevreuse, France. With an impressive portfolio of 18 patents, she has made significant contributions to the field of pharmaceutical science. Her focus on the Basic Proline-rich Lacrimal Protein (BPLP) has the potential to change the landscape of diagnostics and treatment in the medical field.

Latest Patents: Among her latest patents, Catherine has developed innovative pharmaceutical compositions containing peptides derived from human BPLP protein. This invention presents an in vitro method for prognosis, diagnosis, and determination of the evolution of conditions involving altered production of BPLP or its maturation products. Through this method, practitioners can detect or quantify BPLP proteins or their maturation products in biological samples from test subjects, comparing them to control subjects to ascertain health conditions.

Another noteworthy patent pertains to methods for treating pain by administering peptides derived from human BPLP. This work highlights her ongoing commitment to advancing medical diagnostics and therapeutics related to BPLP.

Career Highlights: Catherine has had a fruitful career with notable affiliations, including her time at the Institut Pasteur and the Centre National de la Recherche Scientifique. Her work at these renowned institutions reflects her dedication to advancing scientific knowledge and innovation in her field.

Collaborations: Throughout her career, she has had the privilege of collaborating with esteemed colleagues such as Francois Rougeon and Mario Arala-Chaves. These partnerships have facilitated knowledge exchange and the development of groundbreaking technologies.

Conclusion: Catherine Rougeot stands as a testament to the impact that dedicated inventors can make in the realm of pharmaceutical science. Her numerous patents and contributions highlight her pivotal role in advancing our understanding and treatment of health conditions through innovative methodologies. As the medical field continues to evolve, the implications of her work will undoubtedly resonate for years to come.

This text is generated by artificial intelligence and may not be accurate.